"Gene therapy manufacturing 'is 20 years behind' academic research in gene delivery and is a concern to investors.”
- Louis Maranga, Chief Technical Operations Officer, Voyager Therapeutics
"You can have the fanciest ideas and molecules, but if you can't get them into the cell, they are of no use.”
- Matthew Porteus, co-founder, crispr therapeutics
Ligandal combines targeting peptides with gene therapy.
CRISPR, TALEN, mRNA, DNA and related genome engineering tools do not have effective delivery systems for most addressable cells, tissues and organs. Electroporation and viruses are not sufficient. Viruses can cost $10,000s/milligram to manufacture.
Ligandal maps the cell surface proteome of targeted cells, creating customized peptide targeting ligands that form into nanoparticles. We do this in hours, not months or years, and at a fraction of the cost of viruses.
Ligandal will make gene therapy predictable, safe and rapid. We aim to provide manufacturing and supply chain services for the industry at large, while creating high-value applications for the industry and, most importantly, freeing the world of disease.